101 related articles for article (PubMed ID: 23813660)
1. Integrative analysis of prostate cancer aggressiveness.
Feik E; Schweifer N; Baierl A; Sommergruber W; Haslinger C; Hofer P; Maj-Hes A; Madersbacher S; Gsur A
Prostate; 2013 Sep; 73(13):1413-26. PubMed ID: 23813660
[TBL] [Abstract][Full Text] [Related]
2. Integrative analysis of genomic aberrations associated with prostate cancer progression.
Kim JH; Dhanasekaran SM; Mehra R; Tomlins SA; Gu W; Yu J; Kumar-Sinha C; Cao X; Dash A; Wang L; Ghosh D; Shedden K; Montie JE; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2007 Sep; 67(17):8229-39. PubMed ID: 17804737
[TBL] [Abstract][Full Text] [Related]
3. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
4. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
5. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
6. In-Silico Integration Approach to Identify a Key miRNA Regulating a Gene Network in Aggressive Prostate Cancer.
Cava C; Bertoli G; Colaprico A; Bontempi G; Mauri G; Castiglioni I
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562723
[TBL] [Abstract][Full Text] [Related]
7. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
8. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
[TBL] [Abstract][Full Text] [Related]
9. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score.
Sinha AA; Quast BJ; Korkowski JC; Wilson MJ; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Anticancer Res; 1999; 19(4B):2821-9. PubMed ID: 10652560
[TBL] [Abstract][Full Text] [Related]
10. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
[TBL] [Abstract][Full Text] [Related]
11. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines.
Trojan L; Schaaf A; Steidler A; Haak M; Thalmann G; Knoll T; Gretz N; Alken P; Michel MS
Anticancer Res; 2005; 25(1A):183-91. PubMed ID: 15816537
[TBL] [Abstract][Full Text] [Related]
12. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
[TBL] [Abstract][Full Text] [Related]
13. Genetic aberrations in prostate carcinoma detected by comparative genomic hybridization and microsatellite analysis: association with progression and angiogenesis.
Strohmeyer DM; Berger AP; Moore DH; Bartsch G; Klocker H; Carroll PR; Loening SA; Jensen RH
Prostate; 2004 Apr; 59(1):43-58. PubMed ID: 14991865
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.
Furusato B; Shaheduzzaman S; Petrovics G; Dobi A; Seifert M; Ravindranath L; Nau ME; Werner T; Vahey M; McLeod DG; Srivastava S; Sesterhenn IA
Prostate Cancer Prostatic Dis; 2008; 11(2):194-7. PubMed ID: 17768422
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of Bcl-2 overexpression in surgically treated prostate cancer is not caused by increased copy number or translocation of the gene.
Fleischmann A; Huland H; Mirlacher M; Wilczak W; Simon R; Erbersdobler A; Sauter G; Schlomm T
Prostate; 2012 Jun; 72(9):991-7. PubMed ID: 22024950
[TBL] [Abstract][Full Text] [Related]
16. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.
Yu YP; Landsittel D; Jing L; Nelson J; Ren B; Liu L; McDonald C; Thomas R; Dhir R; Finkelstein S; Michalopoulos G; Becich M; Luo JH
J Clin Oncol; 2004 Jul; 22(14):2790-9. PubMed ID: 15254046
[TBL] [Abstract][Full Text] [Related]
17. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
[TBL] [Abstract][Full Text] [Related]
18. CCR2 expression correlates with prostate cancer progression.
Lu Y; Cai Z; Xiao G; Liu Y; Keller ET; Yao Z; Zhang J
J Cell Biochem; 2007 Jun; 101(3):676-85. PubMed ID: 17216598
[TBL] [Abstract][Full Text] [Related]
19. Expression analysis and prognostic significance of human kallikrein 11 in prostate cancer.
Stavropoulou P; Gregorakis AK; Plebani M; Scorilas A
Clin Chim Acta; 2005 Jul; 357(2):190-5. PubMed ID: 15893744
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.
Kristiansen G; Pilarsky C; Wissmann C; Kaiser S; Bruemmendorf T; Roepcke S; Dahl E; Hinzmann B; Specht T; Pervan J; Stephan C; Loening S; Dietel M; Rosenthal A
J Pathol; 2005 Feb; 205(3):359-76. PubMed ID: 15532095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
